Ionic Polypeptide Complexes for Sustained Peptide Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical compositions of peptidic drugs often result in a sudden burst of drug availability, leading to fluctuations in concentration, reduced stability, increased toxicity, and decreased patient compliance due to frequent administrations, necessitating a need for extended release formulations.
Innovation Solution
The development of an ionic complex comprising a cationic polypeptide and an anionic excipient, such as PEG-carboxylic acid, fatty acid, or anionic phospholipid, which provides a sustained release formulation, enhancing pharmacokinetic properties and reducing undesirable side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptidic drugs are administered in conventional formulations, then rapid absorption and high bioavailability are achieved, but sudden burst of drug availability causes fluctuations in concentration, reduced stability, and increased toxicity
Solution Approach 1:
The drug delivery system is segmented into multiple components: a peptidic drug component and a polypeptide component that forms complexes. This segmentation allows the drug to be released in controlled portions rather than as a sudden burst, reducing concentration fluctuations and toxicity while maintaining stability.
Solution Approach 2:
The polypeptide acts as an intermediary carrier that binds to the peptidic drug through electrostatic interactions. This intermediary mechanism controls the release kinetics, preventing direct rapid absorption and thereby reducing toxicity and instability associated with conventional formulations.
2Duration of action of moving object
If peptidic drugs are administered in conventional formulations, then high drug loading per administration is achieved, but frequent administrations are required leading to decreased patient compliance
Solution Approach 1:
The polypeptide-drug complexes are prepared in advance and administered as pre-formulated compositions. The complexes are designed to maintain therapeutic levels over extended periods, eliminating the need for frequent re-administration and thereby improving patient compliance while extending the duration of pharmacological action.
3Speed
If peptidic drugs are administered in conventional formulations, then rapid onset of action is achieved, but reduced stability and increased fluctuations in concentration occur
Solution Approach 1:
The system employs dynamic control of drug release through the polypeptide-drug complex dissociation rate. The complexes provide initial rapid release for quick onset, then transition to slower release to maintain stable concentrations, achieving both speed and stability through a dynamically adjusted release profile.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ionic complex offers a more gradual drug release, increasing stability and efficacy, reducing toxicity, and improving patient compliance by allowing less frequent administrations, with a pharmacological action duration that can be extended over various dosing intervals.
Implementation Method 1
an ionic complex comprising a cationic polypeptide and an anionic excipient
Data Source
AI summary
The present invention relates to an ionic complex comprising a cationic polypeptide and an anionic excipient selected from: a PEG-carboxylic acid; a fatty acid having 10 or more carbon atoms; an anionic phospholipid; and a combination thereof. The invention also relates to a pharmaceutical composition comprising the ionic complex of the invention and a pharmaceutically acceptable carrier. The cationic polypeptide of the ionic complex has pharmacological activity and the complex can provide a more desirable pharmacokinetic profile for the cationic polypeptide of the complex as compared to the cationic polypeptide alone following administration. As such, the invention also relates to the use of the ionic complex and pharmaceutical composition comprising same to treat a subject suffering from a disease or disorder that is responsive to the cationic polypeptide of the ionic complex.